Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

• Main Authors: Jessica D. Lang (Author), Tuong Vi V. Nguyen (Author), Maren K. Levin (Author), Page E. Blas (Author), Heather L. Williams (Author), Esther San Roman Rodriguez (Author), Natalia Briones (Author), Claudius Mueller (Author), William Selleck (Author), Sarah Moore (Author), Victoria L. Zismann (Author), William P.D. Hendricks (Author), Virginia Espina (Author), Joyce O'Shaughnessy (Author)
• Format: Book
• Published: BMC, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background A subset of triple-negative breast cancers (TNBCs) have homologous recombination deficiency with upregulation of compensatory DNA repair pathways. PIKTOR, a combination of TAK-228 (TORC1/2 inhibitor) and TAK-117 (PI3Kα inhibitor), is hypothesized to increase genomic instability a...